This FAQ explains how aseptic processing, contamination control, and validation protect patients amid sterile injectable failures.
|Articles|January 26, 2018
Metrohm USA Opens New Headquarters in Florida
Author(s)BioPharm International Editors
The company relocated its headquarters to Riverview, Florida.
Advertisement
Metrohm USA announced the opening of its new United Stated headquarters in Riverview, Florida on Jan. 15, 2018. The 90,000-ft2 building includes training facilities for employees and clients, application development laboratories, technical and customer support areas, and a 25,000-ft2 warehouse.
“Metrohm’s dedication to the people that use our instruments and those who support them make us who we are as a company. This new facility demonstrates our commitments as we invest in providing our customers with innovative training facilities and our employees with modern and collaborative work areas,” says Edward Colihan, president and CEO of Metrohm USA, in a company press release.
Source:
Advertisement
Related to this article
Bimekizumab-bkzx (Bimzelx) produced ACR50 joint responses in 54.9% of psoriatic arthritis patients at week 24 vs 43.8% with risankizumab.
VG801 gene therapy improved vision through 12 months in a Stargardt disease trial as VeonGen aligned with FDA on its pivotal phase 3 design.
Matt Trupo, Richard Jaenisch, and Brian Drapeau explore how AI advances biological insights, drug-target discovery, and supply chains.
As access to low Earth orbit expands, space-based research is opening possibilities in drug discovery, formulation, and manufacturing. In Part 1, the authors look at how microgravity changes biology and chemistry in ways that can’t be reproduced on Earth and where it fits from target discovery to life cycle management.
Aldevron and IDT added PE Ultra prime editor mRNA and 6 ABE8e base editor mRNAs to help researchers edit DNA without double-strand breaks.
Shilpa CDMO's $50 million plan adds 10 kL of SPPS reactor capacity in Raichur, India, with its first commercial peptide line opening in December 2026.
Beam Therapeutics’ base-edited cell therapy risto-cel meets its primary endpoint in the BEACON sickle cell disease trial, Amgen’s CD40L antagonist dazodalibep reduces systemic disease activity in the phase 3 OASIZ-301 Sjögren’s disease trial, and ImvivaBio’s allogeneic CD19/BCMA CAR-T CTA313 sustains lupus remission through 12 months.
Advertisement
Advertisement
Trending on BioPharm International
1
AstraZeneca Acquires Omniose, Adding Bioconjugate Vaccine Platform
2
Amgen’s Dazodalibep Reduces Systemic Disease Activity in Phase 3 Sjögren’s Trial
3
The BioPharm Brief: FDA Designations for a Bispecific CAR-T, a BLA for Friedreich’s Ataxia, and Phase 2b MASH Data for Efinopegdutide
4
Efinopegdutide Meets Primary Endpoint in Phase 2b MASH Trial
5